688331.SH
荣昌生物
SSE · Healthcare · Biotechnology · CN
CNY 116.42
−7.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.4B | 3.3B | 1.7B | 1.1B | 772.1M |
| Cost of Revenue | 442.5M | 413.5M | 337.2M | 244.4M | 272.0M |
| Gross Profit | 2.9B | 2.8B | 1.4B | 838.6M | 500.1M |
| Operating Expenses | |||||
| R&D Expense | 1.1B | 1.2B | 1.5B | 1.3B | 982.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 354.5M | 364.3M | 316.7M | 304.2M | 266.3M |
| Selling & Marketing Expense | 1.1B | 1.1B | 948.8M | 775.2M | 440.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.7B | 2.8B | 2.9B | 2.4B | 1.6B |
| Cost and Expenses | 3.1B | 3.2B | 3.2B | 2.6B | 1.9B |
| Operating Income (EBIT) | 1.3B | 722.6M | (1.5B) | (1.5B) | (995.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.3B | 710.4M | (1.5B) | (1.5B) | (998.8M) |
| Income Tax Expense | 486.5K | 748.7K | — | — | — |
| Bottom Line | |||||
| Net Income | 1.3B | 709.6M | (1.5B) | (1.5B) | (998.8M) |
| Earnings from Cont. Ops | 1.3B | 709.6M | (1.5B) | (1.5B) | (998.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.3B | 709.6M | (1.5B) | (1.5B) | (998.8M) |
| Per Share | |||||
| Basic EPS | CN¥2.32 | CN¥1.29 | (CN¥2.73) | (CN¥2.80) | (CN¥1.88) |
| Diluted EPS | CN¥2.32 | CN¥1.29 | (CN¥2.73) | (CN¥2.80) | (CN¥1.88) |
| Revenue Per Share | CN¥5.98 | CN¥5.91 | CN¥3.19 | CN¥2.01 | CN¥1.45 |
| Shares | |||||
| Basic Shares Outstanding | 565.5M | 550.1M | 537.9M | 539.7M | 531.3M |
| Diluted Shares Outstanding | 565.5M | 550.1M | 537.9M | 539.7M | 531.3M |
| Profitability Metrics | |||||
| EBITDA | — | 985.5M | (1.2B) | (1.3B) | (870.0M) |
| D&A | — | 262.9M | 241.6M | 179.3M | 125.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026